Tuesday, April 7, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

NPR advises patients not to miss medical appointments

As the medical community unearths troubling consequences for people who put off routine or emergency health care during the coronavirus pandemic, an urgent message is going out to patients: There are some medical appointments you just shouldn’t put off any longer, even if you’re nervous about venturing into a clinic or emergency room.

In the first days of the COVID-19 pandemic, I was one of many primary care doctors making tough decisions about who needed to be seen in person and who could wait a few weeks. But as weeks have turned into nearly a year, our calculus has changed.

“There was a time, early in the pandemic, when we didn’t know much about this virus. So at that time, I think hospitals and clinics closing — that made sense,” Dr. Ned Sharpless, director of the National Cancer Institute, tells NPR. “But that time is over. We can have patients come in and get these tests and see their doctors in person in a way that is both safe for the caregiver and safe for the patient, and the risk of transmission is low.”

Source: NPR

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!